Photo of Paul Schmidt
Accepting New Patients

Paul H Schmidt, MD, PhD Email Paul Schmidt

Surgical Oncology
Doctor magenta, checkmark badge icon
Mount Sinai Doctors Faculty Practice ?
    • Position
    • Specialties
    • Surgical Oncology
    • Surgery
    • Breast Cancer - Surgery
    • Language
    • English
    • Hospital Affiliations
    • Mount Sinai Beth Israel
    • The Mount Sinai Hospital
    • New York Eye and Ear Infirmary of Mount Sinai
    • Mount Sinai St. Luke's and Mount Sinai West
Request an Appointment
Dr Schmidt is a board certified surgeon specializing in surgical oncology and particularly in care of patients with breast cancer. His background also includes training in Molecular Medicine and Genetics, and post-doctoral experience in cell signaling, cancer biology, and translational research for development of novel targeted therapies. He is the recipient of a National Research Service Award from the National Institutes of Health. Currently he is the director of the Cancer Risk program (CaRE) at the Dubin Breast Center at Mount Sinai and has expertise in management of patients at high risk for breast cancer and other malignancies. This program incorporates individual risk stratification and management through prophylactic surgery, risk reducing therapies, and specialized screening protocols. Dr Schmidt is the co-Principal Investigator of the Breast Cancer Biospecimen Repository and has led the design and development of this tissue collection in conjunction with an accompanying comprehensive clinical information system as a tool for breast cancer research. As a member of the Tisch Cancer Institute, he is also involved in multiple clinical and translational studies through the Dubin Breast Center aimed at improving diagnosis, prognostication, and outcomes for patients diagnosed with breast cancer. Dr Schmidt’s research interests are focused on implementation of truly personalized medicine in breast cancer. Ongoing studies include chemoprevention, development of new blood and tissue biomarkers, utility of neoadjuvant protocols and patient derived tumor models to understand mechanisms of therapeutic resistance.


American Board of Surgery

Clinical Focus


MD, East Tennessee State University

PhD, Medical College of Georgia IMMAG

Residency, Surgery (Gen)
Medical College of Georgia

Fellowship, Surgery Oncology
University of Chicago